Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Gilead's HIV Portfolio Shines as Cell Therapy Sales Decline

Gilead Sciences reported mixed results in its third-quarter earnings, with its HIV franchise driving growth while cell therapy sales continue to face challenges. The company's long-acting HIV pre-exposure prophylaxis (PrEP) medication, Yeztugo, has shown promising early adoption since its June launch in the U.S., contributing to an overall positive outlook for Gilead's HIV business.

NoahAI News11/1/2025

Gilead Seeks Expansion Opportunities Amid Strong HIV Performance and Veklury Decline

Gilead Sciences, a leading pharmaceutical company, is actively pursuing expansion opportunities across multiple therapeutic areas while navigating a mixed financial landscape. The company's recent third-quarter earnings call revealed a complex picture of growth in key sectors offset by declines in others, prompting a strategic focus on dealmaking and portfolio diversification.

NoahAI News10/31/2025

Evommune Sets Sights on $160M IPO Amid Federal Shutdown

Evommune, a California-based biotech company, has announced its intention to raise up to $160 million through an initial public offering (IPO) on the New York Stock Exchange. The company plans to offer nearly 9.4 million shares of common stock priced between $15 and $17 per share, with an additional 30-day option for underwriters to purchase 1.4 million more shares.

NoahAI News10/31/2025

Dexcom Addresses G7 Quality Issues, Expands Type 2 Diabetes Offerings

Dexcom, a leader in diabetes technology, has reported significant progress in addressing quality concerns with its G7 continuous glucose monitor (CGM) while simultaneously expanding its product portfolio for Type 2 diabetes patients. The company's third-quarter financial results reflect these developments, showing strong revenue growth despite recent challenges.

NoahAI News10/31/2025

Corporate Venture Firms Propel Biotech Startups Amid Funding Slowdown

Corporate Venture Firms Step Up to Fill Biotech Funding GapIn a significant shift within the biotechnology startup ecosystem, corporate venture firms have emerged as key players, filling the void left by traditional investors amidst a prolonged funding slowdown. This trend, highlighted by a recent BioPharma Dive analysis, shows that venture funds associated with pharmaceutical giants such as Novo Holdings, Eli Lilly, and Sanofi have become increasingly active in backing privately held companies throughout 2025.

NoahAI News10/31/2025

Nanobiotix Secures $71 Million Funding for Cancer Drug Development

Nanobiotix, a biotechnology company developing innovative cancer treatments, has secured a significant financial lifeline to support the continued development of its Johnson & Johnson-partnered cancer drug. The company has entered into a $71 million non-dilutive funding agreement with HealthCare Royalty (HCRx), providing a crucial boost to its cash reserves and extending its financial runway into early 2028.

NoahAI News10/31/2025

4DMT Secures $420M Deal with Otsuka for Retinal Gene Therapy Rights in Asia-Pacific

4D Molecular Therapeutics (4DMT) has announced a significant partnership with Otsuka Pharmaceutical, selling the Asia-Pacific rights to its promising eye gene therapy, 4D-150. The deal, valued at up to $420 million, aims to accelerate the development and potential commercialization of the therapy for retinal vascular diseases in key markets across the region.

NoahAI News10/31/2025

Young Biotech Executive's Rise Highlights Industry Trends and Challenges

In a rapidly evolving pharmaceutical landscape, the story of Neena Bitritto-Garg, CEO of Ensho Therapeutics, offers a compelling glimpse into the industry's current dynamics. From navigating complex partnerships to launching a startup, Bitritto-Garg's journey reflects broader trends in drug development, market dynamics, and the challenges faced by emerging biotech companies.

NoahAI News10/31/2025

Illumina's Q3 Results Show Resilience Amid China Challenges

Illumina, a leading sequencing technology company, has reported flat revenue for the third quarter of 2025, marking a slight improvement from the previous quarter's decline. The company's performance reflects its ongoing struggle with sales restrictions in China, while also highlighting its ability to grow in other markets.

NoahAI News10/31/2025

Pharmaceutical Industry Update: Earnings Reports Reveal Mixed Results and Market Challenges

Alnylam Pharmaceuticals, a top performer in the biotech sector this year, reported quarterly revenues of $1.25 billion, surpassing analyst estimates by nearly $300 million. The company's key drug Amvuttra generated $685 million in sales, outperforming expectations of $622 million. This success led Alnylam to boost its financial forecasts for the year.

NoahAI News10/31/2025

Lilly's Orforglipron: Balancing Accessibility and Innovation in Obesity Treatment

Eli Lilly's upcoming weight loss pill, orforglipron, is poised to make waves in the pharmaceutical industry as the company navigates the delicate balance between pricing accessibility and funding future research. CEO David Ricks outlined the company's strategy during Lilly's third-quarter earnings call, emphasizing the need to make the drug available to those who need it while ensuring continued investment in R&D.

NoahAI News10/31/2025

Pharmaceutical Industry Faces Widespread Layoffs and Strategic Shifts Amid Challenging Market Conditions

The pharmaceutical industry is experiencing a wave of layoffs and restructuring initiatives as companies grapple with challenging market conditions and the need to reallocate resources. Industry giants including Novo Nordisk, Merck, and Bristol Myers Squibb have announced substantial workforce reductions in recent months.

NoahAI News10/31/2025

«1 2 3 4...67 »